Trials / Terminated
TerminatedNCT03184558
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC
A Phase II, Multi Centre Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated, Locally Advanced and Unresectable or Metastatic Triple Negative Breast Cancer (TNBC) or Triple Negative Inflammatory Breast Cancer (TN-IBC)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- BerGenBio ASA · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, single arm, multi-centre phase II study to assess the anti-tumour activity and safety of bemcentinib (BGB324) in combination with pembrolizumab in participants with previously treated, locally advanced and unresectable, or metastatic TNBC or TN-IBC. The primary objective is objective response rate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bemcentinib; pembrolizumab | Bemcentinib is a selective Axl kinase inhibitor; pembrolizumab is a programmed death receptor-1 (PD-1) inhibitor. |
Timeline
- Start date
- 2017-07-26
- Primary completion
- 2018-08-20
- Completion
- 2018-08-20
- First posted
- 2017-06-12
- Last updated
- 2021-11-09
- Results posted
- 2021-11-09
Locations
17 sites across 4 countries: United States, Norway, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03184558. Inclusion in this directory is not an endorsement.